MXCT insider trading
NasdaqGS HealthcareMAXCYTE, INC.: insider trade history from SEC Form 4 filings.
About MAXCYTE, INC.
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Company website: www.maxcyte.com
MXCT insider activity at a glance
FilingIQ tracks 236 insider transactions for MXCT in filings since Aug 3, 2021. The most recent transaction is dated Jun 17, 2026.
Across the full history, 10 open-market purchases
and 96 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on MXCT insider trades is 63.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest MXCT Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for MXCT?
- FilingIQ tracks 236 Form 4 insider transactions for MXCT (MAXCYTE, INC.), covering filings from Aug 3, 2021 onwards. 0 of those are dated within the last 90 days.
- Are MXCT insiders net buyers or net sellers?
- Across the full Form 4 history for MXCT, 10 transactions (4%) were open-market purchases and 96 (41%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does MXCT insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is MXCT in?
- MAXCYTE, INC. (MXCT) is classified in the Healthcare sector, specifically Medical Devices, with a current market capitalisation of $80.27M.
Methodology & sources
Every MXCT insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.